FDA coupon prompts fast approval of Boehringer Ingelheim drug for first-line lung cancer treatment

The label expansion for Boehringer Ingelheim's Hernexeos comes under an FDA pilot program that expedites regulatory review of products of national interest. The daily drug is now approved as a first-line treatment for HER2-positive non-small cell lung cancer, an indication with few treatment options.

The post FDA credentials lead to fast-track approval of Boehringer Ingelheim drug for first-line use in lung cancer appeared first on MedCity News.